Serial #77307521
DEAD

Serial Number

77307521

Owner

MAP Pharmaceuticals, Inc.

Attorney

Jennifer Lee Taylor

Filing Date

Oct 18, 2007

Add to watchlist:

No watchlists yet
View on USPTO

Serial #77307521 Trademark

Serial Number: 77307521

Serial #77307521 is a trademark filed by MAP Pharmaceuticals, Inc. on October 18, 2007. The trademark is classified under Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). The application is currently no longer active.

Owner Contact Info

MAP Pharmaceuticals, Inc. (26 trademarks)

2400 Bayshore Parkway, Suite 200
Mountain View, CA 94043

Entity Type: 03

Trademark Details

Filing Date

October 18, 2007

Registration Date

Not Registered

Published for Opposition

March 11, 2008

Goods & Services

Pharmaceutical products for use in the treatment of cardiovascular diseases and disorders, urological diseases and disorders, gastrointestinal diseases and disorders, musculoskeletal diseases and disorders, hypertension, inflammation and inflammatory diseases and disorders, metabolic diseases and disorders, infectious diseases and disorders, immunological, bacterial, viral and fungal diseases and disorders, psychiatric diseases and disorders, allergies, diabetes, obesity, stroke, erectile and sexual dysfunction, and hemolytic diseases and disorders; pharmaceutical preparations, namely, cholesterol preparations, osteoporosis preparations, oncological preparations, dermatological preparations, ophthalmologic preparations, smoking cessation preparations, tissue and skin repair preparations and gynecological preparations; drug delivery devices, namely, inhalers containing pre-filled drug cartridges which deliver medication in liquid form via the pulmonary route, either directly to the lungs or for absorption and delivery in systemic circulation for use in the treatment of cardiovascular diseases and disorders, urological diseases and disorders, gastrointestinal diseases and disorders, musculoskeletal diseases and disorders, hypertension, inflammation and inflammatory diseases and disorders, metabolic diseases and disorders, infectious diseases and disorders, immunological, bacterial, viral and fungal diseases and disorders, psychiatric diseases and disorders, allergies, diabetes, obesity, stroke, erectile and sexual dysfunction, and hemolytic diseases and disorders; drug delivery devices, namely, inhalers containing pre-filled drug cartridges which deliver medication in liquid form via the pulmonary route, either directly to the lungs or for absorption and delivery in systemic circulation for use in the delivery of cholesterol preparations, osteoporosis preparations, oncological preparations, dermatological preparations, ophthalmologic preparations, smoking cessation preparations, tissue and skin repair preparations and gynecological preparations

Pharmaceutical research and development; research and development of pharmaceutical preparations for the treatment of cardiovascular diseases and disorders, central nervous system and neurological diseases and disorders, urological diseases and disorders, gastrointestinal diseases and disorders, musculoskeletal diseases and disorders, migraines and headaches, pain, hypertension, inflammation and inflammatory diseases and disorders, metabolic diseases and disorders, respiratory and infectious diseases and disorders, immunological, bacterial, viral and fungal diseases and disorders, psychiatric diseases and disorders, asthma, allergies, diabetes, obesity, stroke, erectile and sexual dysfunction, and hemolytic diseases and disorders; research and development of pharmaceutical preparations, namely, cholesterol preparations, osteoporosis preparations, oncological preparations, dermatological preparations, ophthalmologic preparations, smoking cessation preparations, tissue and skin repair preparations and gynecological preparations; research and development of drug delivery devices, both with and without pre-filled drug cartridges, for delivery of medication via the pulmonary route; medical and scientific research, namely, conducting clinical trials

Filing History

ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILED
Jul 5, 2011 MAB6
ABANDONMENT - NO USE STATEMENT FILED
Jul 5, 2011 ABN6
NOTICE OF APPROVAL OF EXTENSION REQUEST MAILED
Sep 4, 2010 EXRA
SOU EXTENSION 5 GRANTED
Sep 3, 2010 EX5G
SOU EXTENSION 5 FILED
Sep 1, 2010 EXT5
SOU TEAS EXTENSION RECEIVED
Sep 1, 2010 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST MAILED
Apr 27, 2010 EXRA
SOU EXTENSION 4 GRANTED
Apr 26, 2010 EX4G
SOU EXTENSION 4 FILED
Apr 23, 2010 EXT4
SOU TEAS EXTENSION RECEIVED
Apr 23, 2010 EEXT
SOU EXTENSION 3 GRANTED
Nov 9, 2009 EX3G
SOU EXTENSION 3 FILED
Nov 6, 2009 EXT3
SOU TEAS EXTENSION RECEIVED
Nov 6, 2009 EEXT
SOU EXTENSION 2 GRANTED
May 20, 2009 EX2G
SOU EXTENSION 2 FILED
May 19, 2009 EXT2
SOU TEAS EXTENSION RECEIVED
May 19, 2009 EEXT
DIVISIONAL PROCESSING COMPLETE
Nov 18, 2008 DPCC
SOU EXTENSION 1 GRANTED
Nov 18, 2008 EX1G
PAPER RECEIVED
Nov 17, 2008 MAIL
CASE ASSIGNED TO INTENT TO USE PARALEGAL
Nov 17, 2008 AITU
DIVISIONAL REQUEST RECEIVED
Nov 13, 2008 DRRR
SOU EXTENSION 1 FILED
Nov 13, 2008 EXT1
SOU TEAS EXTENSION RECEIVED
Nov 13, 2008 EEXT
NOA MAILED - SOU REQUIRED FROM APPLICANT
Jun 3, 2008 NOAM
PUBLISHED FOR OPPOSITION
Mar 11, 2008 PUBO
NOTICE OF PUBLICATION
Feb 20, 2008 NPUB
LAW OFFICE PUBLICATION REVIEW COMPLETED
Feb 1, 2008 PREV
EXAMINER'S AMENDMENT MAILED
Jan 31, 2008 CNEA
APPROVED FOR PUB - PRINCIPAL REGISTER
Jan 30, 2008 CNSA
EXAMINER'S AMENDMENT ENTERED
Jan 30, 2008 XAEC
EXAMINERS AMENDMENT -WRITTEN
Jan 30, 2008 CNEA
ASSIGNED TO EXAMINER
Jan 29, 2008 DOCK
TEAS/EMAIL CORRESPONDENCE ENTERED
Dec 26, 2007 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Dec 26, 2007 CRFA
ASSIGNED TO LIE
Dec 26, 2007 ALIE
TEAS VOLUNTARY AMENDMENT RECEIVED
Nov 15, 2007 PARI
NOTICE OF DESIGN SEARCH CODE MAILED
Oct 24, 2007 MDSC
NEW APPLICATION ENTERED
Oct 23, 2007 NWAP